Literature DB >> 11130165

[Local cyclosporin A in nummuli after keratoconjunctivitis epidemica. A pilot study].

T Reinhard1, E Godehardt, H G Pfahl, R Sundmacher.   

Abstract

BACKGROUND: Recurrences are common after discontinuing topical steroids against nummular infiltrates following adenoviral keratoconjunctivitis (AK). To avoid the potentially serious side effects of resumed steroid treatment at increased doses we tested topical 2% cyclosporin A (CSA). PATIENTS: We applied four drops of CSA daily to 70 eyes (48 patients) with persistent nummular infiltrates after AK. Treatment began 18.5 months (3-72) after the acute phase of AK. Dose reduction depended on resolution of the nummuli in the individual patients.
RESULTS: Of the 70 eyes 40 responded positively to therapy, 16 showed no change, therapy was stopped in 4 because of ocular discomfort (burning), and in 10 eyes follow-up is still less than 3 months.
CONCLUSIONS: CSA was effective in eliminating or reducing nummuli in the majority of patients. More than one-half of the responding eyes had a complete cure and did not experience recurrences after stopping therapy. We therefore consider topical CSA to be a safe and effective alternative to topical steroids for treating nummular infiltrates after AK.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11130165     DOI: 10.1007/s003470070025

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  11 in total

Review 1.  Epidemic keratoconjunctivitis: the current situation and recommendations for prevention and treatment.

Authors:  Birthe Meyer-Rüsenberg; Ulrike Loderstädt; Gisbert Richard; Paul-Michael Kaulfers; Caroline Gesser
Journal:  Dtsch Arztebl Int       Date:  2011-07-08       Impact factor: 5.594

2.  Comparison of clinical outcome with different treatment regimens in acute adenoviral keratoconjunctivitis.

Authors:  L Asena; E Şıngar Özdemir; A Burcu; E Ercan; M Çolak; D D Altınörs
Journal:  Eye (Lond)       Date:  2017-02-03       Impact factor: 3.775

3.  Effect of 0.05% topical cyclosporine for the treatment of symptomatic subepithelial infiltrates due to adenoviral keratoconjunctivitis.

Authors:  Ilkay Kilic Muftuoglu; Yonca A Akova; Sirel G Gungor
Journal:  Int J Ophthalmol       Date:  2016-04-18       Impact factor: 1.779

4.  [Adenoviral keratoconjunctivitis].

Authors:  U Pleyer; F Birnbaum
Journal:  Ophthalmologe       Date:  2015-05       Impact factor: 1.059

Review 5.  [Topical immunosuppressives after penetrating keratoplasty].

Authors:  F Birnbaum; A Reis; T Reinhard
Journal:  Ophthalmologe       Date:  2007-05       Impact factor: 1.059

Review 6.  Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis.

Authors:  Su-Hsun Liu; Barbara S Hawkins; Sueko M Ng; Mark Ren; Louis Leslie; Genie Han; Irene C Kuo
Journal:  Cochrane Database Syst Rev       Date:  2022-03-03

7.  [Epidemic keratoconjunctivitis. In vivo images of corneal structures with the confocal Rostocker laser scanning microscope (RLSM)].

Authors:  S Knappe; J Stave; R F Guthoff
Journal:  Ophthalmologe       Date:  2005-08       Impact factor: 1.059

8.  [Cyclosporin A eyedrops for keratitis nummularis after adenovirus keratoconjunctivitis].

Authors:  D Böhringer; F Birnbaum; T Reinhard
Journal:  Ophthalmologe       Date:  2008-06       Impact factor: 1.059

9.  Determinants of Outcomes of Adenoviral Keratoconjunctivitis.

Authors:  Cecilia S Lee; Aaron Y Lee; Lakshmi Akileswaran; David Stroman; Kathryn Najafi-Tagol; Steve Kleiboeker; James Chodosh; Amalia Magaret; Anna Wald; Russell N Van Gelder
Journal:  Ophthalmology       Date:  2018-03-27       Impact factor: 12.079

10.  Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis.

Authors:  Seydi Okumus; Erol Coskun; Mehmet Gurkan Tatar; Erdal Kaydu; Ramazan Yayuspayi; Aysegul Comez; Ibrahim Erbagci; Bulent Gurler
Journal:  BMC Ophthalmol       Date:  2012-08-18       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.